CWHM-1552 manufacturers
- CWHM-1552
-
- $48.00
-
2026-07-14
- CAS:2368253-58-9
- Purity: 99.56%
- Supply Ability: 10g
- CWHM-1552
-
- $48.00
-
2026-07-14
- CAS:2368253-58-9
- Purity: 99.56%
- Supply Ability: 10g
|
| | CWHM-1552 Basic information |
| Product Name: | CWHM-1552 | | Synonyms: | CWHM-1552;CWHM1552,CWHM 1552;Benzeneacetamide, N-[(3S,4R)-4-[4-(1,1-difluoroethyl)phenyl]-3-pyrrolidinyl]-4-(dimethylamino)-;CWHM-1552, 10 mM in DMSO | | CAS: | 2368253-58-9 | | MF: | C22H27F2N3O | | MW: | 387.47 | | EINECS: | | | Product Categories: | | | Mol File: | 2368253-58-9.mol |  |
| | CWHM-1552 Chemical Properties |
| Boiling point | 589.7±50.0 °C(Predicted) | | density | 1.19±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 15.31±0.40(Predicted) |
| | CWHM-1552 Usage And Synthesis |
| Description | CWHM-1552 is an orally efficacious inhibitor of P. falciparum with IC50s of 51 nM and 53 nM for 3D7 and Dd2 strain, respectively[1].
IC50: 51 nM (3D7 strain) and 53 nM (Dd2 strain)[1] CWHM-1552 (Compound (-)-32a) (orally; 3-30 mg/kg/day for 4 days) inhibits parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day[1]. CWHM-1552 (i.v. administration; 2 mg/kg/day for 48 hours) has respectable half-lives (2.7 h) and low clearance in mice[1]. CWHM-1552 has good pharmacokinetic properties and oral efficacy in a mouse model of malaria. CWHM-1552 has an in vivo ED90 of P. chabaudi ASS infected Mice[1] | | Uses | CWHM-1552 is an orally efficacious inhibitor of P. falciparum with IC50s of 51 nM and 53 nM for 3D7 and Dd2 strain, respectively[1]. | | in vivo | CWHM-1552 (Compound (-)-32a) (orally; 3-30 mg/kg/day for 4 days) inhibits parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day[1].
CWHM-1552 (i.v. administration; 2 mg/kg/day for 48 hours) has respectable half-lives (2.7 h) and low clearance in mice[1].
CWHM-1552 has good pharmacokinetic properties and oral efficacy in a mouse model of malaria. CWHM-1552 has an in vivo ED90 of <10 mg/kg/day and ED99 of 30 mg/kg/day, respectively[1].
| Animal Model: | P. chabaudi ASS infected Mice[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | Orally; daily for 4 days | | Result: | Inhibited parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day. |
| Animal Model: | Male KM mice[1] | | Dosage: | 2 mg/kg | | Administration: | I.v. administration; daily | | Result: | Had respectable half-lives (2.7 h) and low clearance in mice. |
| | References | [1]. Meyers MJ, et al. 4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl) acetamides. ACS Med Chem Lett. 2019 May, 10(6):966-971. |
| | CWHM-1552 Preparation Products And Raw materials |
|